Are you close to candidate selection? An IND/IMPD enabling drug developability assessment may help in compound consideration.
Drug discovery and development is a complex and iterative process that […]
Greetings from the new CSO
A year and a half after stepping down from the CEO […]
Integrated drug discovery and development services – tailored to your needs
Throughout drug discovery and development, there are numerous scientific hoops to […]
Admescope 2022 lookback
2022 was full of action, and it marked the most successful […]
I have become an Admescopian!
Time goes by fast when having fun – such a cliché, […]
Meet the team: Part 3
Admescope welcomes Dr Laszlo Szilagyi, the newest member of the Business […]
Meet the team: Part 2
As part of our ‘meet the team’ series, Admescope welcomes Leah […]
MIST evaluation toolbox – what is in there? Part 4
The overall aim of the safety metabolism studies is to better […]
Dear all, What a joy it is to address the Admescope […]
MIST evaluation toolbox – what is in there? Part 3
In the first part of this blog series, Dr Johanna Haglund […]
Preclinical characterisation of antibody-drug conjugates – ADME perspective
Antibody drug conjugate (ADC) comprise of a monoclonal antibody and cytotoxic […]
MIST evaluation toolbox – what is in there? Part 2
In Part 1, Dr Johanna Haglund (Head of Safety Metabolism) described […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.